Research Article | Volume 6 - Issue 1 | Article DOI :
Download PDF
Laura Waldron¹*, Caroline Chinchilla², Lisa McMahon³, Shipra Garg⁴, Keith Sacco⁵, Brad Pasternak²
¹Pediatrics, Phoenix Children’s Hospital, Phoenix, AZ, United States
²Gastroenterology, Phoenix Children’s Hospital, Phoenix, AZ, United States
³Pediatric Surgery, Phoenix Children’s Hospital, Phoenix, AZ, United States
?Pediatric Pathology, Phoenix Children’s Hospital, Phoenix, AZ, United States
?Pediatric Allergy & Immunology, Phoenix Children’s Hospital, Phoenix, AZ, United States
Corresponding Author:
Laura Waldron, Pediatrics, Phoenix Children’s Hospital, Phoenix, AZ, United States
Keywords
Inflammatory bowel disease; Tofacitinib; Common variable immunodeficiency; Autoimmune enteropathy; Crohn’s disease;
CVID enteropathy.
Abstract
A significant obstacle to effective treatment of autoimmune enteropathy and Inflammatory Bowel Disease (IBD) in Common Variable Immunodeficiency (CVID) is that both may be refractory to guideline-directed medical management. In this case report, utilization of immunologic testing to characterize activity along JAK/STAT signaling pathways revealed increased activity. As a result, Tofacitinib was successfully initiated to block downstream JAK1/3 signaling in a patient with disease previously refractory to anti-TNF-alpha and anti Il12/23 biologics.
Citation
Waldron L, Chinchilla C, McMahon L, Garg S, Sacco K, et al. (2024) Medically Refractory IBD in a Patient with CVID Responsive to Tofacitinib: A Case Report. SM J Gastroenterol Hepatol 6: 2.
INTRODUCTION
Common Variable Immunodeficiency (CVID) encompasses a clinical diagnosis of recurrent sinopulmonary infections in hypogammaglobulinemic patients over age 4 having inappropriate vaccine responses. Immune dysregulation, particularly autoimmunity and uncontrolled inflammation is the main cause for morbidity and mortality in this cohort [1]. Autoimmune enteropathy and Inflammatory Bowel Disease (IBD) in CVID can be refractory to guideline-directed medical management [2,3]. We describe using a mechanistic approach to characterize increased activity along JAK/STAT signaling pathways for which we successfully initiated off-label Tofacinitib, blocking downstream JAK1/3 signaling in a patient whose GI disease was refractory to anti-TNF alpha and anti-Il12/23 biologics [4].
CASE PRESENTATION
A 10-year-old female with complex past medical history presented to the Emergency Department (ED) with severe abdominal pain two weeks after hospital discharge. Her history was remarkable for CVID, Failure to Thrive (FTT), Insulin-Like Growth Factor 1 (IGF1) receptor mutation (IGF1R c.2984_2986delinsG (p.Arg9995Glyfs*20)), short stature, Vesicoureteral Reflux (VUR), and refractory Crohn’s Disease (CD). She had recently been admitted for elective laparoscopic ileocecectomy due to refractory CD, though her course was complicated by abscess and stricture formation, requiring three weeks of antibiotic therapy. She had previously failed treatment of CD with prednisone, adalimumab, and ustekinumab, as evidenced by persistent abdominal pain, bloody bowel movements, weight loss, and elevated calprotectin, in addition to continued inflammation on endoscopic evaluation (Figure 1).

Figure 1: The images above show the descending colon of the patient before and after tofacitinib treatment. Image A shows erythema, ulceration and granularity of descending colon from EGF performed on September 9, 2022 (approximately 3 months prior to start of Tofacitinib treatment). Image B shows normal mucosa of descending colon from EGD performed on April 14, 2023 (approximately 3 months after start of Tofacitinib treatment).
Upon return to the ED, she was found to have high grade small bowel obstruction. She went to the operating room and was found to have a severely inflamed and friable bowel with dense adhesive disease. She required multiple resections of the small bowel, silo placement, and end ileostomy prior to abdominal closure. Pathology revealed necrotizing granulomatous inflammation, abscess with granulomatous infiltrate and ileum with hemorrhagic ischemia with adhesions (Figure 2).

Figure 2: Image A is a pathology sample from the terminal ileum from September 2022 that shows chronic active ileitis, moderate with epithelioid granulomas (arrows). Image B is a pathology sample from the ascending colon from April 2023 showing chronic colitis with epithelioid granuloma (arrow).
Due to history of CVID, immunology was consulted. sIL2Ra, CXCL9, IL8 were found to be elevated but thought to likely be due to significant T cell activation. Further work up revealed elevated Il-2 receptor, IL 5, IL-10, and Il-6. Il-6 and CRP elevated at presentation to 211 (< = 2.0 pg/mL) and 21.9 (< 0.9 mg/dL) respectively. High dose IVIG was used in lieu of steroids due to postoperative status and continued for 10 days. In that time CRP down trended to 1.6 mg/dL. If IGF1 variant was contributing to clinical presentation, it would follow that pSTAT5 would be decreased on testing as it is down stream of the IGF1 receptor. We checked STAT5 phosphorylation to functionally validate the IGF1 variant - since STAT5bLOF could present with this phenotype ie. CIVD, IBD and short stature. However lab results revealed that pSTAT5 is elevated in this patient, signifying that her IGF1 variant mutation is not contributing to her disease. These results suggest broad activation rendering a jak inhibitor as a possible therapeutic target [5]. Providers chose to use off-label tofacitinib due to history of good response in IBD patients and desire to target JAK 1 and JAK 3 inhibition in treatment. She was subsequently started on this and showed immediate response resulting in discharge from the hospital, with continued TPN to meet nutritional needs. Outpatient follow up 1 month after discharge showed significant improvement meeting 100% of her nutritional needs enterally with a five-pound weight gain and resolution of her abdominal pain.
DISCUSSION
After extensive evaluation, we hypothesize the sequelae of events was secondary to CVID enteropathy rather than refractory CD. CD and CVID enteropathy have overlap in treatment options with biologics, however this patient had little success with adalimumab and ustekinumab [6]. In review of previous biopsies, pathology documented absence/paucity of plasma cells. In the setting of granulomatous inflammation this is specific to CVID enteropathy [7]. Noninfectious sequalae CVID, like enteropathy, pose a risk of significant morbidity [3]. Individualized immunologic work up revealed upregulated Jak-stat pathway, helping guide therapeutic options in our patient. Immunologic work up must be considered in patients with refractory IBD symptoms and CVID to determine the best pharmacologic approach to achieve remission [2]. Providers should also consider testing for inborn errors of immunity in patients refractory to 2 or more IBD standard of care treatment options. Jak inhibitors, such as tofacitinib, may play a significant role in ameliorating the inflammatory response in this population.
Patient and legal guardian aware and consent to submission of this case report and included images for publication.
REFERENCES
1. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012; 119(7): 1650-16557.
2. Hashash JG, Squire J, Francis FF, Binion DG, Cross RK, Farraye FA. An Expert opinion/approach: clinical presentations, diagnostic considerations, and therapeutic options for gastrointestinal manifestations of common variable immune deficiency. Am J Gastroenterol. 2022; 117(11): 1743-1752.
3. Kalha I, Sellin JH. Common variable immunodeficiency and the gastrointestinal tract. Curr Gastroenterol Rep. 2004; 6(5): 377-383.
4. Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017; 77(5): 521-546.
5. Dudek P, Fabisiak A, Zatorski H, Malecka-Wojciesko E, Talar-Wojnarowska R. Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment. J Clin Med. 2021; 10(23): 5660.
6. Malesza IJ, Malesza M, Krela-Kaźmierczak I, Zielińska A, Souto EB, Dobrowolska A, et al. Primary humoral immune deficiencies: overlooked mimickers of chronic immune-mediated gastrointestinal diseases in adults. International Journal of Molecular Sciences. 2020; 21: 5223.
7. Uzzan M, Ko HM, Mehandru S, Cunningham-Rundles C. Gastrointestinal disorders associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD). Curr Gastroenterol Rep. 2016; 18(4): 17.